EMERGENCY USE AUTHORIZATION (EUA) SUMMARY FOR THE
LETSGETCHECKED CORONAVIRUS (COVID-19) TEST

For In vitro Diagnostic Use
Rx Only
For use under Emergency Use Authorization (EUA) only
For use by people 18 years of age or older

The LetsGetChecked Coronavirus (COVID-19) Test will be performed at the LetsGetChecked, Inc. laboratory (PrivaPath Labs d.b.a. LetsGetChecked Labs) certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet the requirements to perform high complexity test.

INTENDED USE

The LetsGetChecked Coronavirus (COVID-19) Test is a nucleic acid amplification in vitro diagnostic test intended for qualitative detection of nucleic acid from the SARS-CoV-2 in anterior nasal swab specimens self-collected by any individuals 18 years and older at home, using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit, including for testing individuals without symptoms or other reasons to suspect COVID-19 when ordered by a healthcare provider. Specimens collected using the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit can be transported at ambient temperature for testing.

Specimens collected with LetsGetChecked Coronavirus (COVID-19) Home collection Kit are individually tested with the LetsGetChecked Coronavirus (COVID-19) Test.

Testing is limited to the LetsGetChecked, Inc. laboratory (PrivaPath Labs d.b.a. LetsGetChecked Labs) certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meets the requirements to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in anterior nasal swabs during the acute phase of infection. Positive results indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Specimens that are self-collected will not be tested with an internal control to confirm that the specimen was properly collected. Self-collected specimens from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly.
Testing with the LetsGetChecked Coronavirus (COVID-19) Test is intended for use by qualified and trained laboratory personnel specifically instructed and trained in the molecular testing and in vitro diagnostic procedures. The LetsGetChecked Coronavirus (COVID-19) Test is only for use under the Food and Drug Administration’s Emergency Use Authorization.

DEVICE DESCRIPTION AND TEST PRINCIPLE

The LetsGetChecked Coronavirus (COVID-19) Home Collection Kit enables the self-collection of an anterior nasal swab sample that is then transported to PrivaPath Labs d.b.a. LetsGetChecked Labs, for RT-PCR testing for SARS-CoV-2 with the LetsGetChecked Coronavirus (COVID-19) Test, when ordered by a healthcare provider. LetsGetChecked will contact all patients receiving positive and invalid test results. Patients with negative test results will be notified by email, phone message and through the website portal.

The LetsGetChecked Coronavirus (COVID-19) Home Collection Kit includes a shipping box, pre-labeled return envelope, Instructions for Use, specimen collection materials (nasal swab and transport media tube), and biohazard bag. Each LetsGetChecked Coronavirus (COVID-19) Home Collection Kit is intended to be returned via Next Day Air shipping at ambient conditions on the same day of sample collection.

Specimens received at the clinical laboratory for testing will undergo review and accessioning prior to acceptance for testing.

The LetsGetChecked Coronavirus (COVID-19) Test will be performed at the LetsGetChecked, Inc. laboratory (PrivaPath Labs d.b.a. LetsGetChecked Labs) High Complexity certified laboratory (Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a. The PrivaPath Labs d.b.a. LetsGetChecked Labs uses the Hologic Aptima SARS-CoV-2 Assay (Panther System) per the Instructions for Use (without modification) for single sample testing without pooling.

REAGENTS AND MATERIALS

LetsGetChecked Coronavirus (COVID-19) Home Collection Kit

<table>
<thead>
<tr>
<th>Shipping box</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polymailer with UN3373</td>
</tr>
<tr>
<td>Return Label (attached to polymailer)</td>
</tr>
<tr>
<td>Specimen biohazard bag with absorbent material</td>
</tr>
<tr>
<td>Nasal swab &amp; transport tube with transport media (Hologic Multitest Swab Collection Kit; Cat.: PRD-03546)</td>
</tr>
</tbody>
</table>
MEDICAL OVERSIGHT AND PROCESS TO BE USED:
LetsGetChecked will use an intake process to enable a LetsGetChecked board certified physician review and authorization of the lab test. Only after this step is completed and the prescription for the test is written, the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit can be shipped to the customer’s home.

LetsGetChecked Labs Accessioning Criteria:
All tests arriving at LetsGetChecked Labs will be checked for the following deficiencies:
● Viral transport media leaked resulting in no sample for testing
● No swab and/or sample transport tube
● Kit not activated on LetsGetChecked.com (sample held until Customer Care can reach patient and advise on activation)

Accession date is greater than 88 hours from the return pick-up date and time (no more than 96 hours from specimen collection time).

CONTROLS TO BE USED WITH THE LETSGETCHECKED CORONAVIRUS (COVID-19) HOME COLLECTION KIT

Each patient sample is run with authorized Hologic Aptima SARS-CoV-2 Assay with applicable assay controls per manufacturer Instructions for Use for single sample testing (without pooling), without any modification.

INTERPRETATION OF RESULTS

All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted. The results interpretation algorithm for the LetsGetChecked Coronavirus (COVID-19) Home Collection Kit is based on the Hologic Aptima SARS-CoV-2 Assay. The algorithm is presented in Table 1.

Table 1. Results Interpretation Algorithm.

<table>
<thead>
<tr>
<th>SARS-CoV-2</th>
<th>Interpretation</th>
<th>Lab Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>Valid sample</td>
<td>SARS-CoV-2 (+) result is valid and can be released</td>
</tr>
<tr>
<td>Negative</td>
<td>Valid sample</td>
<td>SARS-CoV-2 (-) result is valid and can be released</td>
</tr>
<tr>
<td>Invalid</td>
<td>Invalid Result. Repeat extraction and rRT-PCR. If the repeated result remains invalid, collect a new specimen from the patient</td>
<td>SARS-CoV-2 result is invalid and sample analysis is repeated</td>
</tr>
</tbody>
</table>

Patients receiving positive and invalid results will be contacted by the Nursing Team. Patients with negative test results will be notified by email, phone message and through the website portal. Patients will be receiving Patient Fact Sheets with their results. Patients with the invalid result will be receiving a second test kit.
In the case of positive results:

- Individuals will receive a phone call from the Nursing Team and results will be released to patient portal
- Results will be reported by LetsGetChecked Labs to public health agencies as required

PERFORMANCE EVALUATION

1) **The LetsGetChecked Coronavirus (COVID-19) Test Sample Stability Studies**

**Summer conditions:** Stability studies were performed by spiking the SARS-CoV-2 isolate (Cat#NR-52286) obtained from BEI Resources, Manassas, VA directly to the sample transport media containing the clinical lower nasal swab matrix at LoD (20 samples) and 2.5x LoD (10 samples) and negative samples (5). Swabs were left in the transport media throughout the course of the experiment to mimic clinical samples. The samples were subjected to 55°C, sustained for 6 days and tested every 24 hours. The 35 test samples were extracted and assayed with the Hologic Aptima SARS-CoV-2 assay at the final time point of the experiment. The positive and negative samples met the following acceptance criteria up to day 5 of testing.

**Acceptance Criteria**
- LoD samples: ≥ 95% agreement with expected results.
- 2.5 x LoD: = 100% agreement with expected results.
- Negative samples: = 100% agreement with expected results.

**Winter conditions:** Stability studies were performed by spiking the SARS-CoV-2 isolate (Cat#NR-52286) obtained from BEI Resources, Manassas, VA directly to the sample transport media containing the clinical nasal swab matrix at 2x LoD (20 samples) and 5x LoD (10 samples) and negative samples (5). All samples were analyzed on day 0 and then put into a -20°C freezer. All samples were removed daily and allowed to thaw completely. Each day one set of samples was tested and disposed of, while the rest were put back into the freezer until the next day. This was continued through 5 days of freeze-thaw cycles. The study showed 100% agreement with expected results for all samples at time points tested.

The results from the summer and winter shipping stability studies support sample shipping stability of 88 hours (96 hours form specimen collection) for specimens tested with Hologic Aptima SARS-CoV-2 Assay.

2) **Self-Collection Validation**

Two usability studies were conducted to assess user interactions with the LetsGetChecked Coronavirus (COVID-19) Test. In the first study, a total of 55 adults completed the study, of which 38% were over 60 years of age, 46% were between 40 - 59 years, and 16% were between 18 - 39 years old; 42% of participants were male and 58% were female. The majority (54/55) of participants produced self-collected anterior nasal swabs that were
received by the laboratory in a condition that was considered acceptable for testing. The majority of participants reported that they understood the Instructions provided for sample collection and packaging. Upon the completion of the first study, the Instructions for Sample Collection have been updated and a second usability study was undertaken. It included 33 participants of which 48% were over 60 years of age, 46% were between 40 - 59 years, and 6% were between 18 - 39 years old; 39% of participants were male and 61% were female. The study was conducted at simulated at-home environment and the participants were observed during the sample collection and packing process.

All participants produced self-collected nasal swabs that were received by the laboratory in a condition that was considered acceptable for testing. No deviations from the Instructions for Use were noted by staff observing the sample collection.

All samples tested positive for human RNaseP gene (tested using authorized CDC 2019-Novel Coronavirus (2019-nCoV) kit) indicating that all participants successfully collected human biological material.

In addition to completed studies, LetsGetChecked submitted a report to the FDA (within 30 days) summarizing any testing performed with LetsGetChecked Coronavirus (COVID-19) Test including how many kits were requested and sent for home collection, how many kits were shipped and returned according to the instructions, how many specimens had to be rejected during accession and the main reasons for rejection, and the positivity rate of the first LetsGetChecked Coronavirus (COVID-19) Home Collection Kit lot.

**Conclusion**: The LetsGetChecked Coronavirus (COVID-19) Test has demonstrated sample stability and usability that is acceptable to the FDA.

3) **Human Gene Control Evaluation**

Among 5,007 consecutive nasal swab samples self-collected using the LetsGetChecked Coronavirus (COVID-19) Home Collection kit, 100% of the samples tested were found to contain the RNase P gene (cellularity rate of 100%; 95% CI: 99.9%, 100%). The mean and standard deviation of RNase P gene PCR Ct values were similar among sex, age group, race/ethnicity categories and comorbidities.

4) **Analytical and Clinical Performance**

WARNINGS:
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
- The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal, Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

LIMITATIONS:
- The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.
- Specimens that are self-collected will not be tested with an internal control to confirm that the specimen was properly collected. Self-collected specimens from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly;
- The requirement to run a sample adequacy control for all samples that were self-collected will be waived provided that the following disclosure has been acknowledged by the entity utilizing authorized home collection kits and a statement is included in the test reports for specific patients who self-collected a specimen:

<table>
<thead>
<tr>
<th>Acknowledgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Insert Client name) acknowledges it has received the disclosure below:</td>
</tr>
</tbody>
</table>

*Specimens that are self-collected will not be tested with an internal control to confirm that the specimen was properly collected. Self-collected specimens from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly.*

<table>
<thead>
<tr>
<th>Test Report Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimens that are self-collected were not tested with an internal control to confirm that the specimen was properly collected. As such, unobserved self-collected specimens from SARS-CoV-2 positive individuals may yield negative results if the specimen was not collected properly.</td>
</tr>
</tbody>
</table>
**FDA SARS-CoV-2 Reference Panel Testing**

The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded samples and a standard protocol provided by the FDA. The study included a range finding study and a confirmatory study for LoD. Blinded sample testing was used to establish specificity and to confirm the LoD. The extraction method and instrument used were the Aptima SARS-CoV-2 Assay extraction and the Hologic Panther respectively. The results are summarized in the following Table.

**Table 3. Summary of LoD Confirmation Result using the FDA SARS-CoV-2 Reference Panel**

<table>
<thead>
<tr>
<th>Reference Materials Provided by FDA</th>
<th>Specimen Type</th>
<th>Product LoD</th>
<th>Cross-Reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2</td>
<td>Nasal Swab</td>
<td>$7.2 \times 10^2$ NDU/mL</td>
<td>N/A</td>
</tr>
<tr>
<td>MERS-CoV</td>
<td></td>
<td>N/A</td>
<td>ND</td>
</tr>
</tbody>
</table>

NDU/mL = RNA NAAT detectable units/mL  
N/A: Not applicable  
ND: Not detected